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Abstract
In hepatitis C Virus (HCV) high-risk groups, HCV-specific T cell responses have been detected in seronegative, aviremic
persons who have no evidence of HCV infection. Herein, we investigated functional profiles of HCV-specific T-cell responses
in seronegative, aviremic patients of a HCV high-risk group. Seventy seven hemodialysis patients with chronic renal disease
were analyzed by IFN-c ELISpot assays, and eight of 71 (11.3%) seronegative, aviremic patients displayed HCV-specific T-cell
responses. Their HCV-specific memory T cells were characterized by assessing cytokine polyfunctionality, known to provide
antiviral protection. By intracellular staining of IFN-c, TNF-a, IL-2 and MIP-1b, we identified two distinct populations in the
seronegative, aviremic patients: polyfunctional responders and TNF-a-predominant responders. In further analysis, occult
HCV infection was excluded as a cause of the HCV-specific T cell response via secondary nested RT-PCR of HCV RNA in
peripheral blood mononuclear cell samples. HCV-specific T cells targeted multiple epitopes including non-structural
proteins in a single patient, implying that their T cells might have been primed by HCV proteins synthesized within the host.
We conclude that HCV-specific memory T cells of seronegative, aviremic patients arise from authentic HCV replication in the
host, but not from current occult HCV infection. By functional pattern of HCV-specific T cells, there are two distinct
populations in these patients: polyfunctional responders and TNF-a-predominant responders.
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Introduction
Hepatitis C virus (HCV) infection is a major cause of chronic
viral hepatitis that often progresses to liver cirrhosis and
hepatocellular carcinoma [1]. HCV is an enveloped positive-
stranded RNA virus of Flaviviridae transmitted by parenteral routes
[2]. Persons with frequent exposure to blood, blood products, and
contaminated needles are at threat of HCV infection [3]. In fact,
healthcare workers, hemophiliacs, hemodialysis patients, and
injection drug users (IDUs) are all HCV high-risk groups.
HCV infection is determined clinically by the detection of both
anti-HCV antibody and HCV RNA. Seropositivity without
viremia is considered a sign of past HCV infection. HCV-specific
memory T cells have been detected in persons who spontaneously
recovered from past HCV infection [4–6]. Intriguingly, HCV-
specific T cell responses have been detected not only in persons
with past HCV infection but also in seronegative, aviremic persons
who have no evidence of current or past HCV infection [7–13].
These studies detected T cells reactive to HCV antigens by
secreting cytokines such as IFN-c ELISpot assay or intracellular
cytokine staining. HCV-specific T cell responses in seronegative,
aviremic persons have been detected mainly in HCV high-risk
groups such as IDUs, residents of HCV-endemic areas, healthy
family members of HCV-infected patients, and healthcare workers
[7–13]. However, it remains unclear why HCV-specific T cells are
primed in seronegative, aviremic persons. In addition, detailed
characteristics of HCV-specific T cells have not been previously
identified in seronegative, aviremic persons.
HCV-specific T cell responses in seronegative, aviremic persons
can be attributed to several possible causes including occult HCV
infection with extremely low level viral replication [14,15],
heterologous T cell immunity by a cross-reactive epitope [16–
18], transient viral replication without seroconversion [19,20] and
disappearance of anti-HCV antibody long after prior HCV
infection [21].
T cells play a major role in the immune response against HCV.
In particular, T cell-mediated protective immunity has been
shown in chimpanzees that had recovered from previous HCV
infection [22,23]. In these studies, HCV rechallenge resulted in
rapid viral clearance with low peak viremia and attenuated liver
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injury [22–24], and this host protection was mediated by memory
T cells as evidenced by T cell-depletion studies [25,26]. Upon
HCV rechallenge, depletion of CD4+ T cells resulted in chronic
persistent infection [25], while depletion of CD8+ T cells delayed
viral clearance [26].
Recently, T cell-mediated host protection has been shown to be
associated with polyfunctional T cells, which exert several effector
functions simultaneously [27–29]. For example, polyfunctional
HIV-specific CD8+ T cells were maintained in human immuno-
deficiency virus (HIV) long-term nonprogressors [28]. In one
vaccination study, Th1 cell polyfunctionality correlated with
vaccine efficacy, in terms of protection against Leishmania [27].
Therefore, induction of polyfunctional memory T cells is
considered a practical goal in T cell vaccine development.
In the present study, we analyzed HCV-specific T cell responses
in seronegative, aviremic hemodialysis patients and tried to reveal
possible causes of HCV-specific memory T cell induction. We also
characterized HCV-specific memory T cells in detail by assessing
T cell polyfunctionality, and demonstrated that HCV-specific T
cell responders in seronegative, aviremic hemodialysis patients are
classified into two distinct groups, polyfunctional responders and
TNF-a-predominant responders.
Materials and Methods
Ethics Statement
All study samples were obtained following acquisition of the
study participants’ and/or their legal guardians’ written informed
consent, in accordance with the Declaration of Helsinki. This
research protocol was reviewed and approved by the institutional
review board of Yonsei University Severance Hospital.
Hemodialysis patients
Seventy-seven patients (48 males and 29 females), who were on
maintenance hemodialysis due to chronic kidney disease, were
recruited in this study. At the time of enrollment, the mean age
(6SD) of patients was 57.0610.6 years, the mean alanine
aminotransferase (ALT) level was 17.3611.6 U/L, and the
median duration of hemodialysis was 39.2 months. All cases were
negative for anti-HIV. In sera, anti-HCV antibodies were assayed
using Elecsys Anti-HCV Immunoassay (Roche Diagnostics, Basel,
Switzerland). HCV RNA was quantitated by COBAS TaqMan
HCV assay (Roche Diagnostics). The lower detection limit of
HCV RNA assay was 15 IU/mL. Peripheral blood mononuclear
cells (PBMCs) were isolated from whole blood by standard Ficoll-
Paque (GE Healthcare, Uppsala, Sweden) density gradient
centrifugation and cryopreserved. In the case of seronegative,
aviremic patients with HCV-specific T cell responses, whole blood
was obtained a second time to confirm the T cell responses.
HCV overlapping peptides
Six hundred pentadecamer peptides (Mimotopes, Clayton,
Australia), overlapping by 10 amino acids and spanning the
complete HCV genotype 1a (H77) sequence, were resuspended at
20 mg/mL in dimethyl sulfoxide (DMSO). Aliquots of each
peptide suspension were pooled and diluted with phosphate-
buffered saline to obtain 49 mixes designed for a matrix array [30].
Each mix contained 24–25 peptides, and each peptide was present
in 2 mixes (Figure S1A). These 49 mixes were used in direct ex vivo
IFN-c enzyme-linked immunosorbent spot (ELISpot) assays in
each patient.
Direct ex vivo IFN-c ELISpot assay
Direct ex vivo IFN-c ELISpot assays were performed as
previously described [31]. Duplicate cultures of 250,000 PBMCs
were set up in RPMI 1640 containing 5% fetal bovine serum (FBS)
and 2 mM L-glutamine with 49 peptide mixes (each peptide at a
final concentration of 1 mg/ml). DMSO was used as a negative
control. After 30 hours in culture, IFN-c spots were developed.
Spots were counted with an ELISpot reader (CTL, Cleveland,
OH), and the number of specific spots was calculated by
subtracting the mean number of spots in negative control wells
of each ELISpot plate from the mean number of spots in each well
stimulated with an HCV peptide mix.
Intracellular cytokine staining (ICS) and T cell
polyfunctionality assay
Cryopreserved PBMCs were thawed, resuspended in RPMI
1640 containing 5% FBS and 2 mM L-glutamine, and rested
overnight at 37uC. PBMCs were stimulated with an epitope
peptide or a peptide mix (each peptide at a final concentration of
1 mg/ml) in the presence of anti-CD28 and anti-CD49d (1 mg/ml
for each; BD Biosciences, San Jose, CA), and brefeldin A
(GolgiPlug, BD Biosciences) and monensin (GolgiStop, BD
Biosciences) were added 1 hour later. After another 5 hours of
incubation, PBMCs were stained with anti-CD3- V500, anti-CD4-
V450 and anti-CD8-APC-H7 (all from BD Biosciences), permea-
bilized using Cytofix/Cytoperm kit (BD Biosciences) and further
stained with either anti-IFN-c-APC or anti-TNF-a-PE-Cy7 (all
from BD Biosciences). In the assay for T cell polyfunctionality,
anti-CD107a-PE (BD Biosciences) was included in the initial
culture medium and PBMCs were stained with anti-IFN-c-APC,
anti-TNF-a-PE-Cy7, anti-MIP-1b-PerCP-Cy5.5 (all from BD
Biosciences) and anti-IL-2-Alexa Fluor 488 (BioLegend, San
Diego, CA) after permeabilization. FACS analysis was performed
by LSRII flow cytometer (BD Biosciences) and the data were
analyzed using FlowJo software (Treestar, San Carlos, CA). T cells
positive for the various combinations of cytokines and degranu-
lation were quantified and analyzed using a Boolean gating
function in FlowJo software.
Multi-cytokine cytometric bead array (CBA)
PBMCs were stimulated with an epitope peptide or a peptide
mix (each peptide at a final concentration of 1 mg/ml) at 300,000
cells/well of a 96-well U-plate. Culture supernatant was harvested
after 72 hours of incubation, and the concentration of IFN-c,
TNF-a and IL-2 was simultaneously determined using CBA (BD
Biosciences) and LSRII flow cytometer. In selected patients,
concentration of granzyme B in culture supernatants was also
determined using CBA.
Secondary nested RT-PCR for detection of occult HCV
infection
To detect occult HCV infection, secondary nested RT-PCR of
the 59-untranslated region of HCV RNA was performed as
described elsewhere [32–34]. Total RNA was extracted from
PBMCs using the RNeasy mini kit (Qiagen, Valencia, CA) with
on-column deoxyribonuclease digestion. For cDNA synthesis, 200
to 400 ng RNA was reverse transcribed with ReverTraAce-a kit
(Toyobo, Osaka, Japan) using an HCV RNA-specific primer.
These cDNA samples served as templates in the direct round of
PCR amplification (primer pairs used: 59-CTG TGA GGA ACT
ACT GTC TTC and 59-GCG GTT GGT GTT ACG TTT), and
the nested round reaction (primer pairs used: 59-GCA GAA AGC
GTC TAG CCA TGG C and 59-CTG CAA GCA CCC TAT
HCV-Specific T Cells in Seronegative Aviremia
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CAG GCA GT) was performed with the products of the first
round PCR.
For positive cases in secondary nested RT-PCR of HCV RNA,
genotypes of HCV were determined as follows. Briefly, the final
PCR product of 243 bp was purified and cloned into the TOPO
TA cloning vector (Invitrogen, Carlsbad, CA), and genotype was
ascertained by automatically sequencing five clones from each
patient.
Results
Presence of HCV-specific T cell responses in seronegative,
aviremic patients
Among 77 hemodialysis patients with chronic renal disease, one
patient was seropositive without viremia, and five patients were
seropositive with viremia. The other 71 patients were seronegative
and aviremic, meaning they exhibited no clinical evidence of
current or past HCV infection. There were no seronegative
patients with viremia. HCV-specific T cell responses were
evaluated by direct ex vivo IFN-c ELISpot assay of PBMCs in all
patients except the seropositive, aviremic patient. For compre-
hensive analysis, we stimulated PBMCs with 49 matrixed mixes of
600 overlapping peptides covering the complete HCV polyprotein
sequence (Figure S1A). All of the viremic patients and a majority
of seronegative, aviremic patients exhibited insignificant levels of
HCV-specific T cell responses (Figure 1A). In contrast, eight
(11.3%) of the seronegative, aviremic patients displayed obvious T
cell responses against HCV (Figure 1A). This was an unexpected
result as these HCV-specific T cells were detected in patients
without evidence of current or past infection. Figure 1B shows
results of the IFN-c ELISpot assay in response to each peptide
mix.
Conducting the IFN-c ELISpot assay with a matrixed mix of
overlapping peptides enabled us to identify T cell epitopes within
the HCV polyprotein for each patient (Figure S1B and Table 1). T
cell responses to the identified epitopes were confirmed by IFN-c
ICS (Figure 1C). We also identified which T cell subset, CD4+ or
CD8+, was responsible for the HCV-specific IFN-c production in
each patient (Figure 1C and Table 1).
Cytokine profiles of HCV-specific T cells in seronegative,
aviremic patients
We further characterized the HCV-specific T cell responses of
the eight seronegative, aviremic patients by examining their
cytokine profiles. PBMCs were stimulated with an epitope peptide
or a peptide mix, and production of both IFN-c and TNF-a were
investigated in culture supernatants. Intriguingly, five patients
(CMI-1 to CMI-5, group I) produced both IFN-c and TNF-a
following HCV-specific stimulation, whereas three patients (CMI-
6 to CMI-8, group II) produced only TNF-a (Figure 2A). IL-2
production was also assayed and scarcely detected with exception
of one patient (CMI-5, data not shown). In the patients of group II,
TNF-a production by HCV-specific T cells was confirmed by ICS
(Figure 2B). Thus, HCV-specific cytokine profiles distinguish two
unique groups of seronegative, aviremic patients with HCV-
specific cellular immune responses.
Two distinct patterns of T cell polyfunctionality in
seronegative, aviremic patients
Next, we analyzed T cell polyfunctionality by multi-cytokine
ICS to further examine the functional diversity of HCV-specific T
cells. In the multi-cytokine ICS of CD4+ T cells, IFN-c, TNF-a,
IL-2, and MIP-1b were simultaneously assessed. In the patients of
group I, HCV-specific CD4+ T cells were proven to be
polyfunctional, and more than half of HCV-specific CD4+ T cells
produced at least three cytokines (group I in Figure 3). In CMI-1,
for example, 45.6% of NS5B2966–2980-specific CD4
+ T cells
produced IFN-c, TNF-a, and MIP-1b simultaneously (Figure 4A
and 4B). A similar pattern of polyfunctionality was observed
against another epitope, NS5B2921–2935, in the same patient
(Figure S2A and S2B). In the patient with a CD8+ T cell response
(CMI-4), cytotoxic function was also evaluated in a polyfunction-
ality assay by the addition of CD107a staining. As a result, more
than 60% of HCV-specific CD8+ T cells were at least triple-
positive, and a major population was quadruple-positive for IFN-
c, TNF-a, MIP-1b, and CD107a (Figure 4C and 4D). In addition,
HCV-specific CD8+ T cells secreted granzyme B following epitope
peptide stimulation (Figure 4E). In contrast, HCV-specific T cells
from group II were not polyfunctional (Figure 3). When HCV-
specific CD4+ T cells were analyzed, 80–90% produced only a
single cytokine, TNF-a (Figure 5A and 5B). These data
demonstrate that there are two distinct groups, polyfunctional
responders and TNF-a-predominant responders, in seronegative,
aviremic patients who have HCV-specific memory T cells.
Neither occult HCV infection nor heterologous immunity
is a cause of the T cell responses seen in seronegative,
aviremic patients
Recently, occult HCV infection has been demonstrated in
persons negative for HCV RNA by clinical-grade RT-PCR [14].
It was reported not only in patients with cryptogenic liver disease
[35] but also in hemodialysis patients [36]. Since a previous study
reported HCV-specific T cell responses in occult HCV infection
[15], we attempted to detect occult HCV infection in seronegative,
aviremic patients with HCV-specific cellular immune responses.
We performed secondary nested RT-PCR of PBMC samples in all
of the hemodialysis patients and obtained a positive result in three
seronegative, aviremic patients as well as in all five of the patients
positive for HCV RNA by clinical-grade RT-PCR (COBAS
TaqMan HCV assay, Roche Diagnostics) (Table 2). However, the
three patients with occult HCV infection were not among the eight
patients who displayed HCV-specific T cell responses. All eight of
the patients with HCV-specific T cell responses showed no sign of
occult HCV infection by nested PCR. Thus, occult HCV infection
was not a cause of the HCV-specific T cell responses in
seronegative, aviremic patients.
Next, heterologous T cell immunity by a cross-reactive epitope
was considered as a possible cause of the T cell responses seen in
seronegative, aviremic patients. As shown in Table 1, however, T
cells from a single patient were specific for multiple HCV epitopes.
At least two epitopes were recognized by T cells from each patient,
with exception of one, CMI-4 (Table 1). This finding suggested
prior T cell priming by bona fide HCV proteins, and not by cross-
reactive epitopes from other pathogens. In addition, the identified
epitope peptides did not show any significant homology in amino
acid sequence with peptides from other known pathogens by
NCBI database searches. Of interest, T cell epitopes were found
not only in structural proteins but also in non-structural (NS)
proteins (Figure 1B and Table 1). T cell responses to HCV NS
proteins are evidence of de novo synthesis of viral proteins in the
host. Therefore, we concluded that the HCV-specific T cell
responses observed in seronegative, aviremic patients resulted
from prior exposure to HCV, even though there was no serological
or clinical-grade RT-PCR evidence of current or past HCV
infection.
HCV-Specific T Cells in Seronegative Aviremia
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Comparison of different groups of patients in clinical
aspects
In the present study, we identified different groups of
hemodialysis patients according to HCV infection and immune
status. There were chronic HCV-infected group (seropositive and
viremic in clinical-grade RT-PCR) and occult HCV-infected
group (seronegative and aviremic, but positive in nested RT-PCR).
In addition, there were polyfunctional T cell responder group,
TNF-a-predominant T cell responder group and non-responder
group in seronegative, aviremic patients. We compared the
different groups of patients in terms of demographic and clinical
information, including duration of hemodialysis and liver enzymes
Figure 1. HCV-specific T cell responses in seronegative, aviremic hemodialysis patients. (A) Direct ex vivo IFN-c ELISpot assay was
performed to examine HCV-specific T cell responses in PBMCs of 76 hemodialysis patients. Five patients were seropositive with viremia (left side), and
71 patients were seronegative and aviremic (right side). PBMCs were stimulated with the 49 matrix mixes of 600 overlapping peptides covering the
complete HCV polyprotein sequence (Materials and Methods and Figure S1A). The sum of A-X mixes and the sum of AA-YY mixes were calculated
respectively, and their average value was presented for total HCV-specific T cell responses in each patient. Box with dashed lines denotes
seronegative, aviremic patients with obvious T cell responses. (B) In the eight seronegative, aviremic patients with obvious T cell responses (CMI-1 to
CMI-8), the results of IFN-c ELISpot assay were presented by each peptide mix (A to X). Relationship between peptide mixes and HCV proteins are also
displayed. (C) IFN-c ICS was performed to identify the T cell subset responding to HCV epitopes. PBMCs were stimulated with epitope peptides
identified in the IFN-c ELISpot assay in the each patient. FACS dot plots are representative data from two patients, CMI-1 and CMI-4.
doi:10.1371/journal.pone.0062319.g001
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(Table S1). However, there was no significant difference among
groups of patients in demographic and clinical aspects.
Discussion
HCV-specific cellular immune responses have been demon-
strated in seronegative, aviremic persons with no evidence of
current or past HCV infection [7–13]. This phenomenon was
reported in HCV high-risk groups such as IDUs, residents of
HCV-endemic areas, healthy family members of HCV-infected
patients, and healthcare workers [7–13]. Virus-specific T cell
responses generated in the absence of apparent infection have also
been reported with other viruses. In HIV infection, a portion of
seronegative, aviremic persons in the frequent exposure high-risk
group displayed strong T cell responses against HIV [37–39]. In
the present study, we detected HCV-specific T cell responses in
11.3% of seronegative, aviremic hemodialysis patients by direct ex
vivo IFN-c ELISpot assays (Figure 1A). The presence of HCV-
specific T cell responses in seronegative, aviremic persons has
several possible explanations, including occult HCV infection with
extremely low-level viral replication [14,15], and heterologous T
cell immunity by a cross-reactive epitope [16–18]. However, we
showed that occult HCV infection was not a cause of the T cell
responses in seronegative, aviremic patients in this study (Table 2).
In addition, memory T cells against multiple HCV epitopes in a
single patient (Figure 1B and Table 1) suggest that the T cells were
primed by bona fide HCV proteins, not by cross-reactive epitopes
from other pathogens, which is a key element of heterologous
immunity. NCBI database searches also suggest that heterologous
immunity is not the cause of the HCV-specific T cell responses
seen in our study, because the identified HCV epitope peptides did
not exhibit significant homology with peptides derived from other
pathogens. Similarity in the three dimensional structure, rather
than the primary sequence, also needs to be considered in cross-
reactivity of HCV epitopes [40].
Our data indicate that HCV-specific memory T cells in
seronegative, aviremic patients arose from previous exposure to
Table 1. Seronegative, aviremic hemodialysis patients with HCV-specific T cell responses.
Patient
IFN-c SFU per 250,000
PBMCs Responding T cells Epitope peptides
CMI-1 92.0 CD4 NS5B2921–2935, NS5B2966–2980
CD8 N.D.*
CMI-2 39.0 CD4 NS5B2921–2935, NS5B2966–2980
CMI-3 28.8 N.D. NS31506–1520, NS31521–1535, NS4B1881–1895, NS4B1896–1910
CMI-4 33.0 CD8 NS31541–1555
CMI-5 84.3 N.D. core35–43, NS5B2426–2440
CMI-6 49.3 CD4 NS31131–1145, NS5A2006–2020
CMI-7 59.0 CD4 multi-specific
CMI-8 50.9 CD4 multi-specific
*N.D., not determined.
doi:10.1371/journal.pone.0062319.t001
Figure 2. Cytokine profile of HCV-specific T cells in seronegative, aviremic hemodialysis patients. (A) After stimulating PBMCs with an
epitope peptide or a peptide mix for 3 days, culture supernatant was harvested, and the concentrations of IFN-c and TNF-a determined in the culture
supernatant by CBA. There are two groups of patients in terms of cytokine profile: group I, patients with IFN-c and TNF-a responses; group II, patients
with TNF-a-predominant responses. (B) TNF-a ICS was performed in the patients of group II. FACS dot plots are representative data from two
patients, CMI-7 and CMI-8.
doi:10.1371/journal.pone.0062319.g002
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HCV and subclinical transient viral replication without serocon-
version. Previous HCV replication in these patients is evidenced
by T cell specificity for epitopes derived from HCV NS proteins
(Figure 1B and Table 1), which would require de novo synthesis of
viral proteins in the host. In a previous cohort study, HCV-specific
cellular immune responses were detected in self-limited acute
HCV infection without seroconversion [19]. In addition, another
study directly demonstrated that exposure to low doses of HCV
led to HCV-specific T cell responses in chimpanzees, with
transient viral replication [20]. The same study found that HCV
challenge with 1-10 RNA (+) inoculums resulted in priming of
HCV-specific T cells without sustained viremia or seroconversion
[20]. It remains possible that in our patients, anti-HCV antibody
was generated during an acute infection and has over the course of
many years disappeared from circulation. In fact, a previous study
demonstrated that anti-HCV disappeared 20 years after recovery
from acute HCV infection while cellular immune responses
persisted [21]. Clinical implications of HCV-specific T cell
response in seronegative, aviremic persons will require further
investigation. In addition, phenotypic characteristics of HCV-
specific T cells needs to be analyzed in further studies, including
memory markers, activation markers and exhaustion markers.
In the present study, we showed two distinct patterns of T cell
polyfunctionality in seronegative, aviremic patients (Figures 3, 4,
and 5). HCV-specific memory T cells were highly polyfunctional
in some patients (group I in Figure 3), whereas they were TNF-a-
predominant in the others (group II in Figure 3). Recently, T cell
polyfunctionality has been investigated in HIV infection and
vaccination studies [27–29] and it was found that polyfunctional
HIV-specific CD8+ T cells were maintained in HIV long-term
nonprogressors [28]. Furthermore, in a Leishmania vaccination
study, the degree of Th1 cell polyfunctionality was shown to
correlate with vaccine efficacy [27]. In addition, the profound
efficacy of the smallpox vaccine has been attributed to poly-
functionality of virus-specific CD8+ T cells. Taken together,
polyfunctional HCV-specific memory T cells in seronegative,
aviremic patients would be expected to protect against subsequent
exposure to HCV. Intriguingly, a very recent study demonstrated
that polyfunctional HCV-specific T cells were associated with
vaccine-induced control of HCV [41].
In patients with a TNF-a-predominant response, HCV-specific
T cells might not provide antiviral protection upon subsequent
HCV exposure. We can infer the absence of a protective role for
TNF-a-single-positive T cells from a recent study of tuberculosis.
In this study, TNF-a-single-positive Mycobacterium tuberculosis-
specific CD4+ T cells were preferentially detected in active
tuberculosis disease rather than in latent infection [42]. It is
possible that TNF-a-single-positive T cell responses might serve
solely as evidence of T cell priming by exposure to pathogen.
In the present study, we suggest that HCV-specific memory T
cells of seronegative, aviremic patients might result from transient
viral replication without seroconversion or, alternately, from
disappearance of anti-HCV antibody long after prior HCV
infection. If these assumptions prove true, it would suggest that
Figure 3. Polyfunctionality of HCV-specific T cells in seronegative, aviremic hemodialysis patients. PBMCs were stimulated with an
epitope peptide or a peptide mix, and production of IFN-c, TNF-a, IL-2, and MIP-1b was simultaneously assessed in multi-cytokine ICS in order to
evaluate polyfunctionality of HCV-specific CD4+ T cells. In each patient, the fraction of T cells positive for a given number of functions is presented as
bar graphs. In the patient with CD8+ T cell responses (CMI-4), cytotoxic degranulation function was also evaluated by CD107a staining in addition to
multi-cytokine ICS for IFN-c, TNF-a, IL-2, and MIP-1b.
doi:10.1371/journal.pone.0062319.g003
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Figure 4. Polyfunctionality assay of HCV-specific T cells in the patients of group I. Representative examples of polyfunctionality assays of
CD4+ T cells in CMI-1 (A and B) and of CD8+ T cells in CMI-4 (C and D) are presented. In CMI-1, PBMCs were stimulated with NS5B2966–2980 epitope
peptide, and IFN-c, TNF-a, IL-2, and MIP-1b production was assessed (A and B). In CMI-4, PBMCs were stimulated with NS31541–1555 epitope peptide,
and CD107a, IFN-c, TNF-a, IL-2, and MIP-1b production was assessed (C and D). In the culture supernatant of NS31541–1555 peptide-stimulated PBMCs,
concentration of granzyme B was determined by CBA (E). The data are presented by FACS dot plots and the pie graphs show the fraction of T cells
positive for a given number of functions (A and C). Detailed analysis of polyfunctionality is presented with every possible combination of functions (B
and D).
doi:10.1371/journal.pone.0062319.g004
Figure 5. Polyfunctionality assay of HCV-specific T cells in the patients of group II. Representative example of polyfunctionality assays of
CD4+ T cells in CMI-8 is presented. PBMCs were stimulated with NS3 peptide mix, and IFN-c, TNF-a, IL-2, and MIP-1b production were assessed. The
data are presented by FACS dot plots and the pie graph shows the fraction of T cells positive for a given number of functions (A). Detailed analysis of
polyfunctionality is presented with every possible combination of functions (B).
doi:10.1371/journal.pone.0062319.g005
HCV-Specific T Cells in Seronegative Aviremia
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past HCV exposure may be better assessed by HCV-specific T cell
responses than by presence of anti-HCV antibody. In fact, HCV-
specific T cell assays could confirm HCV exposure in indetermi-
nate blood donors [43–45]. However, T cell assays for IFN-c
responsiveness might underestimate HCV exposure since there are
seronegative, aviremic patients who demonstrate a TNF-a-
predominant response. Thus, assays specific for a T cell TNF-a
response might prove superior to assays examining IFN-c
production.
In summary, we show that HCV-specific T cell responses in
seronegative, aviremic hemodialysis patients might result from a
prior, transient viral replication without seroconversion or from
disappearance of anti-HCV long after acute HCV infection has
resolved, but not from current occult HCV infection. We also
demonstrate that HCV-specific T cell responders in seronegative,
aviremic hemodialysis patients are classified into two distinct
groups, polyfunctional responders and TNF-a-predominant re-
sponders. Determining the significance of these responses with
respect to immunology and vaccinology will require further
investigation. In particular, detailed characterization of HCV-
specific T cell polyfunctionality might provide a basis for
understanding of protective immunity against HCV and a strategy
for the development of an HCV vaccine.
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